The transaction generated approximately €1.05 million in net proceeds. GenSight will use the capital for operations and working capital while it prepares structural financing for the RECOVER Phase 3 trial.
The company expects the funding to support operations through late March 2027, subject partly to the number of patients receiving treatment through its French early-access program.
Completing Near-Term Financing
The transaction supplements the company’s October 2026 fundraising and addresses the near-term requirement of up to €2 million previously disclosed by GenSight.
The financing includes approximately 4.2 million ordinary shares, 13.2 million pre-funded warrants, and 17.4 million investor warrants. Full exercise of the warrants could produce an additional €925,669 in gross proceeds.
GenSight is developing gene therapies for retinal neurodegenerative diseases and central nervous system disorders. Its current work includes GS010, also known as LUMEVOQ, which remains available to certain patients through early-access programs.
The company is preparing for regulatory discussions and seeking longer-term financing for the next stage of the program’s development.
KEY QUOTES:
With this financing, we have completed, on schedule, the approximately €2 million raise we announced with our half-year results. We are grateful to Invus and Heights, who have been among our most consistent supporters since November 2024, for standing alongside GenSight once again. Their renewed commitment allows us to approach our upcoming interactions with regulatory agencies with confidence, while we continue to make GS010/LUMEVOQ available to patients through early access and prepare a structural financing for the next phase of its development.
Jan Eryk Umiastowski, Chief Financial Officer of GenSight Biologics

